Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey

被引：3

作者：

Begna, Kebede ^{[1
]}

Al-Kali, Aref ^{[1
]}

Elliott, Michelle ^{[1
]}

Foran, James ^{[2
]}

Gangat, Naseema ^{[1
]}

Hogan, William ^{[1
]}

Hook, Christopher ^{[1
]}

Leis, Jose ^{[3
]}

Litzow, Mark ^{[1
]}

Mesa, Ruben ^{[3
]}

Palmer, Jeanne ^{[3
]}

Pardanani, Animesh ^{[1
]}

Patnaik, Mrinal ^{[1
]}

Rivera, Candido ^{[2
]}

Sproat, Lisa ^{[3
]}

Tibes, Raoul ^{[3
]}

Wolanskyj-Spinner, Alexandra ^{[1
]}

Tefferi, Ayalew ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[2] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA

[3] Mayo Clin, Div Hematol Med Oncol, Scottsdale, AZ USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2017年 / 92卷 / 11期

关键词：

IMATINIB; TRIAL;

D O I：

10.1002/ajh.24866

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：E626 / E627

页数：2

共 3 条

[1] Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [J].

Cortes, Jorge E. ;

Saglio, Giuseppe ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Mayer, Jiri ;

Boque, Concepcion ;

Shah, Neil P. ;

Chuah, Charles ;

Casanova, Luis ;

Bradley-Garelik, Brigid ;

Manos, George ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) :2333-U54

[2] Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial [J].

Kantarjian, Hagop M. ;

Hochhaus, Andreas ;

Saglio, Giuseppe ;

De Souza, Carmino ;

Flinn, Ian W. ;

Stenke, Leif ;

Goh, Yeow-Tee ;

Rosti, Gianantonio ;

Nakamae, Hirohisa ;

Gallagher, Neil J. ;

Hoenekopp, Albert ;

Blakesley, Rick E. ;

Larson, Richard A. ;

Hughes, Timothy P. .

LANCET ONCOLOGY, 2011, 12 (09) :841-851

[3]

2017, NCCN GUIDELINES VERS

← 1 →